Manufacturer¿s ref.No: (b)(4).Information regarding patient date of birth and weight were not provided.The initial reporter phone and email address are not available / reported.[conclusion]: the event was reported via the membrane study.A 69-year-old female patient with a history of controlled hypertension underwent meningeal artery (mma) embolization using the trufill n-bca (631500 / jy1048) on (b)(6) 2022.The patient experienced left-sided headache on the same day as the surgery, which was reported to be moderate.The event was evaluated as possibly related to the study device and study procedure.It was reported as not related to the subdural hematoma (sdh) medication.The patient was prescribed medication for the reported headache and the event resolved.Based on complaint information, the device remains implanted and is thus not available for evaluation.A review of manufacturing documentation associated with this lot (jy1048) presented no issues during the manufacturing or inspection processes related to the reported complaint.There were no nonconformances related to device manufacture or inspection.The device will not be returned for analysis and therefore, no further investigation can be performed at this time.No determination of causes and possible contributing factors could be made.As a result, the investigation will be closed.The investigator evaluated the headache as being possibly related to the study device.Hence, this will be considered as a product complaint and the file will be processed accordingly as a mdr reportable event.As part of the post market surveillance program, information from this complaint is trended for statistical signals and corrective / preventive action may be triggered at a later time.Since there was no evidence to suggest the event was related to a manufacturing or design issue, no corrective actions will be taken at this time.This report is being submitted pursuant to the provisions of 21 cfr, part 4.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by cerenovus, or its employees that the report constitutes an admission that the product, cerenovus, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Missing information from this report is identified as blank; this information was not provided in the reported event or available at the time of report submission.The manufacturer will submit a supplemental report if new facts arise which materially alter information submitted in a previous mdr report.Additional information will be submitted within 30 days of receipt.
|